Biotech | April 15, 2026
ten23 health expands APAC footprint with new Tokyo office, appoints Noriko Utsumi
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
The goal is to better support drug developers as programs move from laboratory research into clinical trials
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
Subscribe To Our Newsletter & Stay Updated
